• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioDelivery Sciences appoints Ernest De Paolantonio CFO

BioDelivery Sciences appoints Ernest De Paolantonio CFO

October 22, 2013
CenterWatch Staff

BioDelivery Sciences International, a specialty pharmaceutical company, has appointed Ernest R. De Paolantonio chief financial officer and corporate secretary.

De Paolantonio has over 35 years of varied financial and business experience in the pharmaceutical industry, and his skill set is intended to broaden BDSI's executive level expertise as the company continues its evolution from a R&D and outlicensing business into a commercial stage enterprise.

In addition to overall responsibility for BDSI's finance function, the company expects to leverage De Paolantonio's involvement in manufacturing, supply chain and other commercialization activities, particularly as BDSI looks to finalize its commercial options for BUNAVAIL, an NDA for which currently is under review by the FDA. Similar experience will be valuable as BDSI's moves toward completion of the phase III program for BEMA Buprenorphine for chronic pain, which is partnered with Endo, and in exploring other business development opportunities.

For the past five years, De Paolantonio has been the chief financial officer of CorePharma, a private specialty generic company. De Paolantonio was directly involved in the financial and commercial strategy to establish their proprietary labeled portfolio of products. In addition, he was in finance and controller positions in roles of increasing responsibility at Colombia Laboratories, where he was also responsible for business development and logistics, including supply chain management for the company's first commercial product launch. He had various financial and controller positions at Taro Pharmaceuticals, Watson Pharmaceuticals and Danbury Pharmaceutical.  De Paolantonio began his career in finance at GlaxoSmithKline, where he spent over 17 years.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing